Principles of curative and palliative cancer surgery

01Purpose and principlesWhat the treatment does and how it fits into care.

Cancer surgery is planned around tumour biology, anatomical extent and the whole treatment sequence. En-bloc removal follows tissue planes and avoids violating tumour. The required margin and nodal approach differ by cancer, so an operation that is adequate for one site may be oncologically incomplete for another. Imaging, pathology and specialist surgical review establish whether disease is resectable and whether preoperative systemic therapy or radiotherapy offers a better sequence.

Fitness assessment identifies cardiopulmonary reserve, frailty, nutrition, anaemia, diabetes, renal function and treatment toxicity that change risk. Optimisation should be proportionate to urgency and expected benefit. Enhanced recovery combines patient preparation, evidence-based anaesthesia, early mobilisation, nutrition and complication surveillance. A palliative operation needs especially explicit comparison with endoscopic, radiological, radiotherapy and medical alternatives because recovery time may consume limited life.

The postoperative MDT integrates final pathology with recovery and patient preferences. Positive margins, nodal disease, pathological response and molecular findings may alter adjuvant treatment. Surveillance should be tumour-specific and accompanied by rehabilitation, stoma, fertility, sexual, lymphoedema and psychological support where relevant.

Key points

Curative surgery aims for complete oncological removal with an appropriate margin and regional staging where relevant; tumour rupture and unplanned piecemeal excision can destroy that opportunity.
Resectability describes whether anatomy permits adequate removal, while operability describes whether the person can tolerate the procedure; they are related but not interchangeable.
Neoadjuvant treatment may downstage disease or test biology before surgery; adjuvant treatment addresses residual microscopic risk after resection.
Palliative surgery treats obstruction, bleeding, perforation, pain or other local harm when complete cure is not realistic and benefit exceeds recovery burden.
Prehabilitation, nutrition, smoking cessation, anaemia management and medication planning can reduce complications without becoming an indefinite barrier to treatment.
Consent must include intent, alternatives, stoma or organ-loss possibilities, functional consequences, recurrence risk and the chance that exploration will not permit resection.
Pathology must report tumour type, stage elements, response, margins and nodes using the current RCPath dataset, because operative success is not judged by appearance alone.
Postoperative deterioration may reflect bleeding, leak, sepsis, thrombosis, cardiopulmonary failure or adrenal and metabolic complications and requires early escalation.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Potentially resectable disease

Staging shows disease confined enough for an oncological operation with an acceptable anticipated margin and functional result.

Borderline anatomy

Vascular contact, multivisceral involvement or limited metastasis requires specialist review rather than automatic refusal or unplanned local surgery.

High operative risk

Frailty, poor cardiopulmonary reserve, malnutrition or organ dysfunction may change approach after reversible problems and alternatives are considered.

Palliative local complication

Obstruction, bleeding, pain, fistula or perforation may justify surgery, stent, ablation or radiotherapy according to speed and burden.

Postoperative emergencyRed flag

Tachycardia, hypotension, rising lactate, respiratory decline, severe pain or reduced urine output can signal leak, bleeding, sepsis or thrombosis.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Tumour-specific staging imagingFirst step
Why
Define local planes, nodes and distant disease before committing to operation.
Interpretation and limitations
Use specialist protocol and review at MDT; unexpected metastasis or vascular involvement can change sequence or intent.
02
Histological diagnosis
Why
Confirm tumour type and biology before major treatment where tissue is safely obtainable.
Interpretation and limitations
Biopsy route should preserve surgical planes; some emergencies or highly characteristic lesions require pathway-specific exceptions.
03
Cardiopulmonary and frailty assessment
Why
Estimate perioperative reserve and identify modifiable risk.
Interpretation and limitations
Combine functional history, examination and selected testing; a score supports but does not replace anaesthetic and surgical judgement.
04
Nutritional and laboratory assessment
Why
Detect malnutrition, anaemia, renal, hepatic, coagulation and metabolic risk.
Interpretation and limitations
Correct clinically meaningful deficits without delaying time-sensitive cancer treatment beyond the likely optimisation benefit.
05
Final surgical pathology
Why
Determine margins, nodes, response and pathological stage.
Interpretation and limitations
Use RCPath dataset and current staging system; close or positive margins require tumour-specific MDT interpretation.

04Treatment approachPreparation, options, escalation and aftercare.

01PlanAgree oncological sequenceFirst stepDefinitivePotentially operable cancer is discussed before definitive local treatment.

1Confirm tissue, stage, biological subtype and resectability in the specialist MDT, including whether neoadjuvant treatment improves the route.
2Assess fitness, frailty, nutrition and patient goals, then compare operation with radiotherapy, systemic and supportive alternatives.
3Consent for intent, margin, organ loss, stoma, functional effects, complications and the possibility of unresectable findings.

02OperateProtect oncological integrityPreferredSurgery is selected as the preferred local treatment.

1Use the tumour-specific en-bloc technique, planned access and nodal strategy, avoiding rupture and unplanned piecemeal removal.
2Provide protocol-led thrombosis, antibiotic, analgesic, glycaemic and enhanced-recovery care with clear responsibility for devices and drains.
3EscalationEscalate early physiological deterioration and investigate bleeding, leak, sepsis, thrombosis or cardiopulmonary failure rather than attributing it to normal recovery.

03ReviewUse pathology and recoveryThe final specimen and postoperative course are available.

1Present margins, nodes, stage, response and biomarkers at MDT and determine whether adjuvant treatment is indicated and tolerable.
2Address stoma, nutrition, pain, mobility, lymphoedema, fertility, sexual and psychological rehabilitation alongside wound recovery.
3Enter tumour-specific surveillance with named ownership, warning symptoms and a plan for recurrence or late surgical complications.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Reduces perioperative venous thromboembolism risk alongside mechanical measures and early mobilisation when bleeding risk permits.

Enoxaparin for perioperative thromboprophylaxis

A common higher-risk surgical prophylaxis dose is 40 mg subcutaneously once daily. Use the authorised local start time; for eligible abdominal surgery NICE specifies at least 7 days, and after major abdominal cancer surgery consider extending to 28 days, with renal, weight and bleeding adjustments.

Coordinate dosing with surgery and neuraxial procedures; review active bleeding, platelet count, renal function, low or high body weight and previous heparin-induced thrombocytopenia. This is prophylaxis, not the treatment dose for established thrombosis.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Trend observations, urine output, pain, wound, drains and laboratory markers, escalating tachycardia or physiological change before overt collapse.
Review thrombosis, pulmonary, cardiac, delirium, glycaemic and nutritional risks daily during major recovery.
Track final pathology and MDT recommendation so adjuvant decisions occur within the intended postoperative window.
Monitor function, weight, stoma or organ-specific rehabilitation and patient-reported recovery after discharge.
Use the tumour surveillance schedule and investigate new symptoms independently rather than waiting for the next routine scan.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Resectable is anatomical

A technically removable tumour may still have biology or patient risk that favours another sequence, while expert centres can resect disease deemed impossible locally.

Margins are tumour-specific

A numerical distance cannot be interpreted without site, surgical plane, specimen orientation and pathology standard.

Palliation can be invasive

An operation intended to relieve symptoms may have substantial recovery and mortality, so less invasive alternatives deserve explicit comparison.

Tachycardia is a warning

Persistent postoperative tachycardia can precede leak, bleeding, sepsis or embolism and should not be dismissed as pain automatically.

Pathology completes surgery

The operative note describes the procedure; only integrated pathological assessment establishes margins, nodal burden and response.

08Common pitfallsFrequent interpretation and management errors.

01
Operating before complete staging and MDT review.
02
Confusing resectability with physiological operability.
03
Biopsying or excising a mass through an oncologically harmful plane.
04
Presenting palliative surgery as low burden.
05
Delaying escalation of postoperative tachycardia.
06
Losing final pathology or adjuvant ownership.